Zacks Research Comments on Omnicell, Inc.’s Q2 2024 Earnings (NASDAQ:OMCL)

Omnicell, Inc. (NASDAQ:OMCLFree Report) – Stock analysts at Zacks Research decreased their Q2 2024 EPS estimates for shares of Omnicell in a research report issued to clients and investors on Thursday, March 21st. Zacks Research analyst M. Mondal now expects that the company will post earnings of $0.07 per share for the quarter, down from their previous forecast of $0.08. The consensus estimate for Omnicell’s current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Omnicell’s Q3 2024 earnings at $0.08 EPS, FY2024 earnings at $0.12 EPS, Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.11 EPS and FY2025 earnings at $0.30 EPS.

Several other analysts also recently weighed in on the company. Wells Fargo & Company decreased their price objective on Omnicell from $28.00 to $26.00 and set an “equal weight” rating for the company in a report on Friday, February 9th. Benchmark reduced their price target on shares of Omnicell from $42.00 to $38.00 and set a “buy” rating for the company in a report on Friday, February 9th. Finally, Barclays started coverage on shares of Omnicell in a research note on Wednesday, January 3rd. They set an “underweight” rating and a $33.00 price objective on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Omnicell presently has an average rating of “Hold” and a consensus price target of $42.20.

Check Out Our Latest Analysis on Omnicell

Omnicell Price Performance

Shares of OMCL stock opened at $28.40 on Monday. Omnicell has a twelve month low of $25.69 and a twelve month high of $77.14. The company has a current ratio of 2.52, a quick ratio of 2.22 and a debt-to-equity ratio of 0.48. The stock has a fifty day simple moving average of $29.56 and a two-hundred day simple moving average of $35.71. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -63.11 and a beta of 0.74.

Omnicell (NASDAQ:OMCLGet Free Report) last announced its quarterly earnings results on Thursday, February 8th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.22. The firm had revenue of $258.85 million during the quarter, compared to analyst estimates of $256.00 million. Omnicell had a positive return on equity of 3.43% and a negative net margin of 1.78%.

Institutional Trading of Omnicell

Hedge funds have recently modified their holdings of the company. Belpointe Asset Management LLC raised its stake in shares of Omnicell by 92.2% during the 1st quarter. Belpointe Asset Management LLC now owns 494 shares of the company’s stock worth $29,000 after acquiring an additional 237 shares in the last quarter. Versant Capital Management Inc increased its position in Omnicell by 561.4% during the 3rd quarter. Versant Capital Management Inc now owns 549 shares of the company’s stock valued at $25,000 after buying an additional 466 shares in the last quarter. Penserra Capital Management LLC raised its stake in Omnicell by 180.8% in the second quarter. Penserra Capital Management LLC now owns 629 shares of the company’s stock valued at $46,000 after buying an additional 405 shares during the last quarter. Covestor Ltd boosted its holdings in Omnicell by 424.2% in the first quarter. Covestor Ltd now owns 844 shares of the company’s stock worth $109,000 after acquiring an additional 683 shares in the last quarter. Finally, KBC Group NV purchased a new stake in shares of Omnicell during the fourth quarter worth about $38,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Company Profile

(Get Free Report)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Recommended Stories

Earnings History and Estimates for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.